22 Feb, 2024 02:42 PM
INOVIQ Limited (ASX:IIQ or INOVIQ) is excited to announce the successful completion of its breast cancer study.
In a 2023 clinical validation study (n=483), INOVIQ’s SubB2M/CA15-3 test dete...read more
22 Feb, 2024 12:20 PM
Description
The securities of INOVIQ Ltd (‘IIQ’) will be placed in trading halt at the request of IIQ, pending it releasing an announcement. Unless ASX decides otherwise, the sec...read more
21 Feb, 2024 09:47 AM
Sydney, Australia – 21 February 2024 – Radiopharm Theranostics Limited (ASX:RAD), a developer of a world class platform of radiopharmaceutical products for both diagnostic and therapeuti...read more
14 Feb, 2024 09:12 AM
SYDNEY, AUSTRALIA – 14 February 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing nov...read more
06 Feb, 2024 12:02 PM
Further to Radiopharm Theranostics Limited (ASX:RAD) (Radiopharm or Company) announcement earlier today, the issue of shares under the Share Subscription Agreement is amended as below and attached.
...read more
06 Feb, 2024 10:09 AM
-- Up to A$12.5 million investment by US institutional investor, Lind Partners.
-- Under a Share Subscription Agreement, RAD will receive A$1.2 million, with up to a further A$11.3 million in fundi...read more
31 Jan, 2024 10:51 AM
Sydney, Australia, 31 January 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to provide a summary of its...read more
31 Jan, 2024 10:32 AM
“Those who know me from my role as Chairman of PolyNovo (ASX: PNV), know how excited I am to lead a company dedicated to saving lives and improving patient outcomes. We all have family and fri...read more
30 Jan, 2024 08:32 AM
-- Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall Survival of 35.5 months in first line non-small cell lung cancer (1L NSCLC) patients expressing PD-L1 (TPS...read more
30 Jan, 2024 08:20 AM
-- FY23 Revenue of US$22.2m, up 89.4% on pcp2 with 2H FY23 revenue of US$12.1m in line with 2H FY23 guidance of US$12m-14m provided in October 2023.
-- 4Q FY23 Product Sales of US$7.1m, up 123.5% o...read more